In January 2025, a warning for severe gastrointestinal adverse reactions was added
Understanding the difference between semaglutide and GLP-1 is essential for patients and clinicians navigating diabetes and weight management therapies
At Internal Medicine and Family Practice in Joliet, Dr
Stone of Northwestern Universitys Feinberg School of Medicine, who helped draft the new guidelines
Finally, Tirzepatide is a dual GIP and GLP-1R agonist that stimulates both receptors, potentially offering greater metabolic benefits than GLP-1 agonism alone and enabling mechanistic interplay studies
3,4 GLP-1RAs mimic the action of endogenous GLP-1, activating GLP-1R, thereby enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing food intake through central appetite suppression